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Abstract
Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia
definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working
Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has
built over the last decade. This paper presents our updated findings.
Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia.
Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a
lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper
on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low
muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of
severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and
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confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify
and characterise sarcopenia.
Conclusions: EWGSOP2’s updated recommendations aim to increase awareness of sarcopenia and its risk. With these
new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions
that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to pre-
vent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
Keywords: sarcopenia, muscle strength, physical performance, muscle assessment, EWGSOP2, older people
Introduction: sarcopenia 2018
In 2010, the European Working Group on Sarcopenia in
Older People (EWGSOP) published a sarcopenia definition
that was widely used worldwide; this definition fostered
advances in identifying and caring for people at risk for or
with sarcopenia [1]. In early 2018, the Working Group met
again (EWGSOP2) to determine whether an update to the
definition of sarcopenia was justified. This meeting took
place 10 years after the gathering of the original EWGSOP,
and an update was deemed necessary to reflect scientific
evidence that has accumulated since then.
In the decade since EWGSOP’s initial work, researchers
and clinicians have explored many aspects of sarcopenia.
Expert groups worldwide have published complementary
definitions of sarcopenia [2–4], and researchers have made
remarkable strides in understanding muscle and its roles in
health and in disease [5, 6]. Sarcopenia is now formally
recognised as a muscle disease with an ICD-10-MC
Diagnosis Code that can be used to bill for care in some
countries [7, 8].
Even though healthcare professionals today are better at
recognising sarcopenia, many research findings have not yet
been translated into clinical practice. To this end, EWGSOP2
uses the newest evidence to delineate clear criteria and tools
that define and characterise sarcopenia in clinical practice and
in research populations. EWGSOP2 emphasises that practi-
tioners have ever-increasing possibilities for preventing, delay-
ing, treating, and sometimes even reversing sarcopenia by way
of early and effective interventions.
Health and healthcare costs of untreated sarcopenia
Optimal care for people with sarcopenia is essential because
the condition has high personal, social and economic bur-
dens when untreated [9]. In terms of human health, sarcope-
nia increases risk of falls and fractures [10, 11]; impairs
ability to perform activities of daily living [12]; is associated
with cardiac disease [13], respiratory disease [14] and cogni-
tive impairment [15]; leads to mobility disorders [2]; and con-
tributes to lowered quality of life [16], loss of independence
or need for long-term care placement [17–19], and death
[20]. In financial terms, sarcopenia is costly to healthcare sys-
tems. The presence of sarcopenia increases risk for hospital-
isation and increases cost of care during hospitalisation [21].
Among older adults who are hospitalised, those with
sarcopenia on admission were more than 5-fold more likely
to have higher hospital costs than those without sarcopenia
[22]. Results of a large, community-based study in the Czech
Republic showed that direct healthcare costs were more than
2-fold higher for older people with sarcopenia than for those
without [23]. In a study of older people in the community, in
assisted-living facilities, or in residential living facilities,
researchers found that lower gait speed and chair stand were
potential drivers of disability in activities of daily living
(ADL) and that such disability was associated with lower
quality of life (QoL) and higher healthcare costs in these tar-
get groups [9]. In another study, patients with sarcopenia had
significantly elevated costs of care during hospitalisation—
regardless of whether they were younger or older than 65
years [24].
Filling the gaps for sarcopenia awareness, care and
research design
Many aspects of the epidemiology and pathophysiology of
sarcopenia are better understood today than 10 years ago.
Researchers have identified links between muscle pathology
and adverse health outcomes, and studies have also pro-
vided evidence that certain treatment strategies can help
prevent or delay adverse consequences.
Such new insights led EWGSOP2 to review, ‘What is
new?’ and ‘How can we use this knowledge to improve care
for people with sarcopenia and to guide future research
studies?’ These insights include:
• First, sarcopenia has long been associated with ageing and
older people, but the development of sarcopenia is now
recognised to begin earlier in life [25], and the sarcopenia
phenotype has many contributing causes beyond ageing
[26, 27]. These insights have implications for interventions
that prevent or delay development of sarcopenia.
• Second, sarcopenia is now considered a muscle disease
(muscle failure), with low muscle strength overtaking the
role of low muscle mass as a principal determinant [11,
28–30]. This change is expected to facilitate prompt iden-
tification of sarcopenia in practice.
• Third, sarcopenia is associated with low muscle quantity
and quality, but these parameters are now used mainly in
research rather than in clinical practice. Muscle mass and
muscle quality are technically difficult to measure accur-
ately [31–34].
A. J. Cruz-Jentoft et al.
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• Fourth, sarcopenia has been overlooked and undertreated
in mainstream practice [35], apparently due to the com-
plexity of determining what variables to measure, how to
measure them, what cut-off points best guide diagnosis
and treatment, and how to best evaluate effects of thera-
peutic interventions [36]. To this end, EWGSOP2 aims to
provide clear rationale for selection of diagnostic mea-
sures and cut-off points relevant to clinical practice.
To enhance awareness and care for sarcopenia, the
EWGSOP2 has updated its definition and diagnostic strat-
egies in 2018. Specific goals for the updates were to: (1)
build a sarcopenia definition that reflects recent advances in
scientific, epidemiological, and clinical knowledge about
skeletal muscle, (2) identify variables that best detect sarco-
penia and predict outcomes, and determine best tools for
measuring each variable, (3) advise cut-off points for mea-
sured variables and (4) recommend an updated screening
and assessment pathway that is easy to use in clinical
practice.
EWGSOP2 meetings, methods and endorsement by
scientific organisations
EWGSOP2 was organised by the European Geriatric
Medicine Society (EuGMS) to include two groups of parti-
cipants—a 16-member writing group and a 13-member
extended group. Original members of the EWGSOP were
invited to participate, and other relevant European
researchers in the field were identified and recruited by
feedback from involved experts and societies. The writing
group met face-to-face 1–2 February 2018 near Madrid to
identify how the definition and diagnostic characteristics
needed to be updated, to begin the process of seeking con-
sensus on key diagnostic and care strategies, and to desig-
nate topical areas for additional literature searches.
Following this meeting, literature searches were con-
ducted, and a preliminary draft of the manuscript was pre-
pared and circulated for review among members of the
writing and extended groups. Feedback was provided by
email, and content was revised. Then a second face-to-face
meeting of the writing group took place on 4 June 2018 in
Amsterdam to discuss open questions and to achieve further
consensus for final recommendations. This second draft was
again opened for discussion by members of the Writing
Group and Extended Group to produce the final draft.
All EWGSOP2 members participated in manuscript
content review throughout the process, and all were polled
for consensus agreement on the final content. Once com-
pleted, the manuscript was reviewed and endorsed by scien-
tific societies: EuGMS, the European Society for Clinical
and Economic Aspects of Osteoporosis, Osteoarthritis and
Musculoskeletal Diseases (ESCEO), the European Society
for Clinical Nutrition and Metabolism (ESPEN),
International Association of Gerontology and Geriatrics
European Region (IAGG-ER) and the International
Osteoporosis Foundation (IOF).
Sarcopenia: operational definition
Sarcopenia is a progressive and generalised skeletal muscle
disorder that is associated with increased likelihood of
adverse outcomes including falls, fractures, physical disability
and mortality. The original operational definition of sarcope-
nia by EWGSOP was a major change at that time, as it
added muscle function to former definitions based only on
detection of low muscle mass [1]. In these revised guidelines,
muscle strength comes to the forefront, as it is recognised
that strength is better than mass in predicting adverse out-
comes [11, 28, 29, 37]. Muscle quality is also impaired in sar-
copenia; this term has been used to describe micro- and
macroscopic aspects of muscle architecture and composition.
Because of technological limits, muscle quantity and muscle
quality remain problematic as primary parameters to define
sarcopenia [31, 32, 34]. Detection of low physical perform-
ance predicts adverse outcomes, so such measures are thus
used to identify the severity of sarcopenia.
In its 2018 definition, EWGSOP2 uses low muscle
strength as the primary parameter of sarcopenia; muscle
strength is presently the most reliable measure of muscle
function (Table 1). Specifically, sarcopenia is probable when
low muscle strength is detected. A sarcopenia diagnosis is
confirmed by the presence of low muscle quantity or qual-
ity. When low muscle strength, low muscle quantity/quality
and low physical performance are all detected, sarcopenia is
considered severe.
Techniques for evaluating muscle quantity are available
in many but not all clinical settings. As instruments and
methods to evaluate muscle quality are developed and
refined in the future, this parameter is expected to grow in
importance as a defining feature of sarcopenia. Physical per-
formance was formerly considered part of the core defin-
ition of sarcopenia, but others have used it as an outcome
measure. We now propose using physical performance to
categorise the severity of sarcopenia.
To apply this definition in practice, this EWGSOP2
paper reviews tests and tools used for assessing muscle
properties and performance, and it presents an updated
algorithm for sarcopenia case-finding, diagnosis and severity
determination.
Identifying sarcopenia in clinical practice
and in research
Validated tests and tools for current use
A wide variety of tests and tools are now available for charac-
terisation of sarcopenia in practice and in research (Table 2)
[38, 39]. Tool selection may depend upon the patient (disabil-
ity, mobility), access to technical resources in the healthcare
test setting (community, clinic, hospital or research centre), or
the purpose of testing (progression monitoring, or monitor-
ing rehabilitation and recovery). In the next sections, general
descriptions of validated tests and tools are provided, and
pros and cons for use of each method are noted.
Sarcopenia: revised European consensus on definition and diagnosis
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Finding sarcopenia cases
In clinical practice, case-finding may start when a patient
reports symptoms or signs of sarcopenia (i.e. falling, feeling
weak, slow walking speed, difficulty rising from a chair or
weight loss/muscle wasting). In such cases, further testing
for sarcopenia is recommended [2].
EWGSOP2 recommends use of the SARC-F question-
naire as a way to elicit self-reports from patients on signs
that are characteristic of sarcopenia. SARC-F can be readily
used in community healthcare and other clinical settings.
The SARC-F is a 5-item questionnaire that is self-reported
by patients as a screen for sarcopenia risk [12]. Responses
are based on the patient’s perception of his or her limita-
tions in strength, walking ability, rising from a chair, stair
climbing and experiences with falls. This screening tool was
evaluated in three large populations—the African American
Health Study, Baltimore Longitudinal Study of Aging and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Choosing tools for sarcopenia case finding and for measurement of muscle strength, muscle mass and physical per-
formance in clinical practice and in research
Variable Clinical practice Research studies Video for practical instruction, reference
Case finding SARC-F questionnaire
Ishii screening tool
SARC-F Malmstrom et al. (2016) [12]
Ishii et al. (2014) [40]
Skeletal muscle
strength
Grip strength Grip strength Roberts et al. (2011) [41]
Chair stand test (chair rise test) Chair stand test (5-times sit-to-stand) American Academy of Orthotists &
Prosthetists
https://www.youtube.com/watch?v=_jPl-
IuRJ5A
Skeletal muscle
mass orSkeletal
muscle quality
Appendicular skeletal muscle mass
(ASMM) by Dual-energy X-ray
absorptiometry (DXA)*
ASMM by DXA Schweitzer (2015) [42]
Mitsiopoulos (1998) [43]
Whole-body skeletal muscle mass (SMM)
or ASMM predicted by Bioelectrical
impedance analysis (BIA)*
Whole-body SMM or ASMM by Magnetic
Resonance Imaging (MRI, total body protocoI)
Shen (2004) [44]
Sergi (2017) [45]
Maden-Wilkinson (2013) [46]
Heymsfield (1990) [47]
Kim (2002) [48]
Yamada (2017) [49]
Mid-thigh muscle cross-sectional area by Computed
Tomography (CT) or MRI
Lee (2004) [50]
Lumbar muscle cross-sectional area by CT
or MRI
Lumbar muscle cross-sectional area by CT or MRI Van der Werf (2018) [51]
Derstine (2018) [52]
Muscle quality by mid-thigh or total body muscle
quality by muscle biopsy, CT, MRI or Magnetic
resonance Spectroscopy (MRS)
Goodpaster (2000) [53]
Reinders (2016) [54]
Grimm (2018) [55]
Distefano (2018) [56]
Ruan (2007) [57]
Physical
performance
Gait speed Gait speed NIH Toolbox 4 Meter Walk Gait Speed
Test
https://www.nia.nih.gov/research/labs/
leps/short-physical-performance-
battery-sppb
https://www.youtube.com/watch?v=
xLScK_NXUN0
Short physical performance battery (SPPB) SPPB Short Physical Performance Battery
Protocol
https://research.ndorms.ox.ac.uk/prove/
documents/assessors/
outcomeMeasures/SPPB_Protocol.pdf
NIH Toolbox
https://www.nia.nih.gov/research/labs/
leps/short-physical-performance-
battery-sppb
Timed-up-and-go test (TUG) TUG Mathias (1986) [40]
400-meter walk or long-distance corridor
walk (400-m walk)
400-m walk Newman (2006) [41]
*Sometimes divided by height2 or BMI to adjust for body size.
Table 1. 2018 operational definition of sarcopenia
Probable sarcopenia is identified by Criterion 1.
Diagnosis is confirmed by additional documentation of Criterion 2.
If Criteria 1, 2 and 3 are all met, sarcopenia is considered severe.
(1) Low muscle strength
(2) Low muscle quantity or quality
(3) Low physical performance
A. J. Cruz-Jentoft et al.
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the National Health and Nutrition Examination study [12],
and was likewise used in a study of Chinese men and
women [58]. In these populations, the SARC-F was valid
and consistent for identifying people at risk of sarcopenia-
associated adverse outcomes.
SARC-F has a low-to-moderate sensitivity and a very
high specificity to predict low muscle strength [59]. As
such, SARC-F will mostly detect severe cases. We recom-
mend SARC-F as a way to introduce assessment and treat-
ment of sarcopenia into clinical practice. SARC-F is an
inexpensive and convenient method for sarcopenia risk
screening. A project is underway to translate and validate
SARC-F in multiple different world languages [60]. Since
SARC-F is self-reported by the patient, results reflect per-
ceptions of adverse outcomes that matter to the patient.
Alternatively, clinicians may prefer a more formal case-
finding instrument for use in clinical populations where sar-
copenia is likely [61]. For example, the Ishii screening test is
a method that estimates the probability of sarcopenia using
an equation-derived score based on three variables—age,
grip strength and calf circumference [40].
Measuring sarcopenia parameters
Muscle strength Measuring grip strength is simple and inex-
pensive. Low grip strength is a powerful predictor of poor
patient outcomes such as longer hospital stays, increased
functional limitations, poor health-related quality of life and
death [28, 29]. Accurate measurement of grip strength
requires use of a calibrated handheld dynamometer under
well-defined test conditions with interpretive data from
appropriate reference populations [41]. Grip strength corre-
lates moderately with strength in other body compartments,
so it serves as a reliable surrogate for more complicated
measures of arm and leg strength. Because of its ease of
use, grip strength is advised for routine use in hospital prac-
tice, in specialty clinical settings, and in community health-
care [28, 29, 62–64]. The Jamar dynamometer is validated
and widely used for measuring grip strength, although use
of other brands is being explored [65]. When measurement
of grip is not possible due to hand disability (e.g. with
advanced arthritis or stroke), isometric torque methods can
be used to measure lower limb strength [66].
The chair stand test (also called chair rise test) can be
used as a proxy for strength of leg muscles (quadriceps mus-
cle group). The chair stand test measures the amount of time
needed for a patient to rise five times from a seated position
without using his or her arms; the timed chair stand test is a
variation that counts how many times a patient can rise and
sit in the chair over a 30-second interval [64, 67, 68]. Since
the chair stand test requires both strength and endurance,
this test is a qualified but convenient measure of strength.
Muscle quantity Muscle quantity or mass can be estimated
by a variety of techniques, and there are multiple methods
of adjusting the result for height or for BMI [46, 69, 70].
Muscle quantity can be reported as total body Skeletal
Muscle Mass (SMM), as Appendicular Skeletal Muscle Mass
(ASM), or as muscle cross-sectional area of specific muscle
groups or body locations.
Magnetic resonance imaging (MRI) and computed tom-
ography (CT) are considered to be gold standards for non-
invasive assessment of muscle quantity/mass [64].
However, these tools are not commonly used in primary
care because of high equipment costs, lack of portability,
and the requirement for highly-trained personnel to use the
equipment [64]. Moreover, cut-off points for low muscle
mass are not yet well defined for these measurements.
Dual-energy X-ray absorptiometry (DXA) is a more
widely available instrument to determine muscle quantity
(total body lean tissue mass or appendicular skeletal muscle
mass) non-invasively, but different DXA instrument brands
do not give consistent results [31, 32, 71]. DXA is presently
favored by some clinicians and researchers for measuring
muscle mass [31]. Fundamentally, muscle mass is correlated
with body size; i.e. individuals with a larger body size nor-
mally have larger muscle mass. Thus, when quantifying
muscle mass, the absolute level of SMM or ASM can be
adjusted for body size in different ways, namely using
height squared (ASM/height2), weight (ASM/weight) or
body mass index (ASM/BMI) [72]. There is an ongoing
debate about the preferred adjustment and whether the
same method can be used for all populations.
An advantage of DXA is that it can provide a reprodu-
cible estimate of ASM in a few minutes when using the
same instrument and cut-off points. A disadvantage is that
the DXA instrument is not yet portable for use in the com-
munity, as needed for care in countries that favor ageing-in-
place. DXA measurements can also be influenced by the
hydration status of the patient.
Bioelectrical impedance analysis (BIA) [62] has been
explored for estimation of total or ASM. BIA equipment
does not measure muscle mass directly, but instead derives
an estimate of muscle mass based on whole-body electrical
conductivity. BIA uses a conversion equation that is cali-
brated with a reference of DXA-measured lean mass in a
specific population [49, 73–75]. BIA equipment is affordable,
widely available and portable, especially single-frequency
instruments. Since estimates of muscle mass differ when dif-
ferent instrument brands and reference populations are used,
we advise use of raw measures produced by the different
devices along with the cross-validated Sergi equation for
standardisation [74, 76]. BIA prediction models are most
relevant to the populations in which they have been derived,
and the Sergi equation is based on older European popula-
tions. Age, ethnicity and other related discrepancies between
those populations and patients should be considered in the
clinic. In addition, BIA measurements can also be influenced
by hydration status of the patient. For affordability and port-
ability, BIA-based determinations of muscle mass may be
preferable to DXA; however, more study is necessary to val-
idate prediction equations for specific populations [75, 77].
As stated previously, muscle mass is correlated with
body size, so SMM or ASM can be adjusted for body size
in different ways, i.e. using height squared (ASM/height2),
Sarcopenia: revised European consensus on definition and diagnosis
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weight (ASM/weight) or body mass index (ASM/BMI)
[72]. The authors make no recommendation to adjust for
body size, but adjustment can be made if data are available
for a relevant normative population.
Although anthropometry is sometimes used to reflect
nutritional status in older adults, it is not a good measure of
muscle mass [78]. Calf circumference has been shown to
predict performance and survival in older people (cut-off
point <31 cm) [79]. As such, calf circumference measures
may be used as a diagnostic proxy for older adults in set-
tings where no other muscle mass diagnostic methods are
available.
Physical performance Physical performance has been defined
as an objectively measured whole-body function related to
locomotion. This is a multidimensional concept that not
only involves muscles but also central and peripheral ner-
vous function, including balance [80]. Physical performance
can be variously measured by gait speed, the Short Physical
Performance Battery (SPPB), and the Timed-Up and Go
test (TUG), among other tests. It is not always possible to
use certain physical performance measures, such as when a
patient’s test performance is impaired by dementia, gait dis-
order or a balance disorder.
Gait speed is considered a quick, safe and highly reliable
test for sarcopenia, and it is widely used in practice [81].
Gait speed has been shown to predict adverse outcomes
related to sarcopenia—disability, cognitive impairment,
need for institutionalisation, falls and mortality [82–85]. A
commonly used gait speed test is called the 4-m usual walk-
ing speed test, with speed measured either manually with a
stopwatch or instrumentally with an electronic device to
measure gait timing [86, 87]. For simplicity, a single cut-off
speed ≤0.8 m/s is advised by EWGSOP2 as an indicator
of severe sarcopenia.
The SPPB is a composite test that includes assessment
of gait speed, a balance test, and a chair stand test [88]. The
maximum score is 12 points, and a score of ≤ 8 points indi-
cates poor physical performance [1, 64].
The TUG evaluates physical function. For the TUG
test, individuals are asked to rise from a standard chair,
walk to a marker 3 m away, turn around, walk back and sit
down again [89].
The 400-m walk test assesses walking ability and endur-
ance. For this test, participants are asked to complete 20
laps of 20 m, each lap as fast as possible, and are allowed
up to two rest stops during the test.
Each of these physical performance tests (gait speed,
SPPB, TUG, 400-m walk) can be performed in most clin-
ical settings. In terms of its convenience to use and ability
to predict sarcopenia-related outcomes, gait speed is
advised by EWGSOP2 for evaluation of physical perform-
ance [67]. The SPPB also predicts outcomes [90], but it is
more often used in research than in clinical assessment
because the battery of tests takes at least 10 min to adminis-
ter. Likewise, the 400-m walk test predicts mortality but
requires a corridor more than 20 m long to set up the
testing course [91]. The TUG has also been found to pre-
dict mortality [92].
Alternative or new tests and tools
A variety of methods are being used or evaluated to deter-
mine the quantity and quality of muscle and impact of sar-
copenia on the patient’s QoL. These diagnostic measures
are being tested for validity, reliability and accuracy and may
play a relevant role in the future. For use in practice, tools
need to be cost-effective, standardised and repeatable by
practitioners in a variety of clinical settings and across dif-
ferent patient populations [78, 93].
Lumbar 3rd vertebra imaging by computed tomography
For patients with cancer, computed tomography (CT) has
been used to image tumors and their response to treatment,
and this technique has also been shown to give practical and
precise measures of body composition. In particular, CT
images of a specific lumbar vertebral landmark (L3) corre-
lated significantly with whole-body muscle [94, 95]. As a
result, this imaging method has been used to detect low mus-
cle mass, even in patients with normal or high body weights,
and it can also predict prognosis [96, 97]. L3-CT imaging is
not limited to patients with cancer; this parameter has been
used as a predictor of mortality and other outcomes in the
intensive care unit [98] and in those patients affected by liver
disease [99]. Quantification of lumbar L3 cross-sectional area
has also been done by MRI [42].
With ever-increasing needs to quantify muscle and
detect sarcopenia in early stages, high-resolution imaging is
expected to be more widely used in the future—initially in
research studies, and ultimately in clinical practice.
Mid-thigh muscle measurement
Mid-thigh imaging (by MRI or CT) has also been used in
research studies, as it is a good predictor of whole-body
skeletal muscle mass and very sensitive to change [50, 94,
96, 100]. Mid-thigh muscle area is more strongly correlated
with total body muscle volume than are lumbar muscle
areas L1–L5 [42].
Psoas muscle measurement with computed tomography
CT-based measurement of the psoas muscle has also been
reported as simple and predictive of morbidities in certain
conditions (cirrhosis, colorectal surgery) [101, 102]. However,
because psoas is a minor muscle, other experts argue that it
is not representative of overall sarcopenia [103, 104]. Further
studies are needed to verify or reject use of this method.
Muscle quality measurement
Muscle quality is a relatively new term, referring both to
micro- and macroscopic changes in muscle architecture and
composition, and to muscle function delivered per unit of
muscle mass [33]. Highly-sensitive imaging tools such as
A. J. Cruz-Jentoft et al.
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MRI and CT have been used to assess muscle quality in
research settings, e.g. by determining infiltration of fat into
muscle and using the attenuation of the muscle [54, 93,
105].
Alternatively, the term muscle quality has been applied
to ratios of muscle strength to appendicular skeletal muscle
mass [106, 107] or muscle volume [108]. In addition, mus-
cle quality has been assessed by BIA-derived phase angle
measurement [93].
As yet, there is no universal consensus on assessment
methods for routine clinical practice. In the future, assess-
ments of muscle quality are expected to help guide treat-
ment choices and monitor response to treatment.
Creatine dilution test
Creatine is produced by the liver and kidney and is also
ingested from a diet rich in meat. Creatine is taken up by
muscle cells, where a portion is irreversibly converted each
day to phosphocreatine, a high-energy metabolite. Excess
circulating creatine is changed to creatinine and excreted in
urine. The excretion rate of creatinine is a promising proxy
measure for estimating whole-body muscle mass.
For a creatine dilution test, an oral tracer dose of
deuterium-labelled creatine (D3-creatine) is ingested by a
fasting patient; labelled and unlabelled creatine and creatin-
ine in urine are later measured using liquid chromatography
and tandem mass spectrometry [109]. Total body creatine
pool size and muscle mass are calculated from D3-creatin-
ine enrichment in urine. Creatine dilution test results correl-
ate well with MRI-based measures of muscle mass and
modestly with measures from BIA and DXA [110, 111].
The creatine dilution test is mostly used in research at this
time, so further refinement is needed to make this method-
ology practical for use in clinical settings.
Ultrasound assessment of muscle
Ultrasound is a widely used research technique to measure
muscle quantity, to identify muscle wasting, and also as a
measure of muscle quality. It is reliable and valid and is
starting to be used at the bedside by trained clinicians.
Ultrasound is accurate with good intra- and inter-observer
reliability, even in older subjects [112]. Assessment of pen-
nate muscles such as the quadriceps femoris can detect a
decrease in muscle thickness and cross-sectional area within
a relatively short period of time, thus suggesting potential
for use of this tool in clinical practice, including use in the
community [112, 113].
The use of ultrasound has recently been expanded in
clinical practice to support the diagnosis of sarcopenia in
older adults. The EuGMS sarcopenia group recently pro-
posed a consensus protocol for using ultrasound in muscle
assessment, including measurement of muscle thickness,
cross-sectional area, fascicle length, pennation angle and
echogenicity [114]. Echogenicity reflects muscle quality,
since non-contractile tissue associated with myosteatosis
shows hyper-echogenicity [115, 116]. Thus, ultrasound has
the advantage of being able to assess both muscle quantity
and quality.
A systematic review on the use of ultrasound to assess
muscle in this population concluded that the tool was reli-
able and valid for the assessment of muscle size in older
adults, including those with comorbid conditions such as
coronary artery disease, stroke, and chronic obstructive pul-
monary disease [117]. Ultrasound was shown to have good
validity to estimate muscle mass as compared to DXA,
MRI and CT. While data are available for older adults,
more research is needed to validate prediction equations for
those with varying health conditions and functional status
[116–119].
Specific biomarkers or panels of biomarkers
The development and validation of a single biomarker
might be an easy and cost-effective way to diagnose and
monitor people with sarcopenia. Potential biomarkers could
include markers of the neuromuscular junction, muscle pro-
tein turnover, behaviour-mediated pathways, inflammation-
mediated pathways, redox-related factors and hormones or
other anabolic factors [120]. However, because of the com-
plex pathophysiology of sarcopenia, it is unlikely that there
will be a single biomarker that can identify the condition in
the heterogeneous population of young and old people [78].
The development of a panel of biomarkers must instead be
considered, including potential serum markers and tissue
markers [120, 121]. The implementation of a multidimen-
sional methodology for the modelling of these pathways
could provide a way to stratify risk for sarcopenia, facilitate
the identification of a worsening condition and provide
monitoring of treatment effectiveness [121].
SarQoL questionnaire
From a patient’s perspective, it is important to have sarco-
penia treatment plans that address QoL issues. To this end,
the SarQoL tool is a self-administered questionnaire for
people with sarcopenia [16, 122–124]. SarQoL identifies
and predicts sarcopenia complications that may later impact
the patient’s quality of life. SarQoL assists the healthcare
provider in assessing a patient’s perception of his or her
physical, psychological and social aspects of health. The
SarQoL tool has been validated as consistent and reliable,
and it can be used in clinical care and in research studies
[16]. The sensitivity of SarQoL to patient status changes
over time needs validation in longitudinal studies. Once val-
idated, SarQoL may serve as a proxy measure of treatment
efficacy. To facilitate widespread use of the SarQoL tool, it
has been translated into multiple languages.
Defining cut-off points for sarcopenia tests
Cut-off points depend on the measurement technique and
on the availability of reference studies and populations. The
original EWGSOP consensus paper did not advise specific
cut-off points, and disputes over cut-off points have
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hampered research and development in the field due to lack
of study consistency. More recently, the Asian Working
Group on Sarcopenia developed an EWGSOP-based con-
sensus that specified cut-off points for diagnostic variables
[4]. The cut-off points in the Asian consensus proved to be
very useful for implementation of recommended sarcopenia
care. Thus, EWGSOP2 has opted to provide recommenda-
tions for cut-off points for different parameters to increase
harmonisation of sarcopenia studies (Table 3).
The current EWGSOP recommendations focus on
European populations and use of normative references
(healthy young adults) [26] whenever possible, with cut-off
points usually set at −2 standard deviations compared to
the mean reference value. In specific circumstances, we
advise use of −2.5 standard deviations for more conserva-
tive diagnosis [26]. For measures such as gait speed and
strength, results depend upon stature, so we recommend
use of regional normative populations when available. For
EWGSOP2 cut-off points, we opted to use round figures,
with the confidence that the minor reduction in accuracy
will be overcome by ease of use.
Practical algorithm: sarcopenia case-
finding, diagnosis and severity
Here, EWGSOP2 updates its algorithm for sarcopenia
case-finding, diagnosis and severity determination. The rea-
soning for this update is logical and practical—to make the
algorithm consistent with our 2018 updated sarcopenia def-
inition, and to make it straightforward in order to foster its
use in clinical settings. Specifically, we recommend a path-
way of Find-Assess-Confirm-Severity (F-A-C-S; Figure 1)
for use across clinical practices and in research studies.
In clinical practice, EWGSOP2 advises use of the
SARC-F questionnaire to find individuals with probable
sarcopenia. We advise use of grip strength and chair stand
measures to identify low muscle strength. To generate evi-
dence that confirms muscle of low quantity or quality, we
recommend evaluation of muscle by DXA and BIA meth-
ods in usual clinical care, and by DXA, MRI or CT in
research and in specialty care for individuals at high risk of
adverse outcomes. We advise measures of physical per-
formance (SPPB, TUG and 400-m walk tests) to assess
severity of sarcopenia.
Sarcopenia development
Time course
Muscle mass and strength vary across a lifetime—generally
increasing with growth in youth and young adulthood,
being maintained in midlife and then decreasing with age-
ing. In young adulthood (up to ~40 years of age), maximal
levels, which are higher in men than in women, are reached
(Figure 2) [26]. Beyond the age of 50 years, loss of leg mus-
cle mass (1–2% per year) and loss of strength (1.5–5% per
year) have been reported [129].
Interestingly, there is a positive association between birth
weight and muscle strength, which is maintained across the
life course [130]. In the initial stages of sarcopenia develop-
ment, an individual may be above the threshold of low phys-
ical performance and is very likely to be above the threshold
of disability. While genetic and lifestyle factors can hasten
muscle weakening and progression toward functional impair-
ment and disability, interventions including nutrition and exer-
cise training seem to slow or reverse these processes [131].
Therefore, to prevent or delay sarcopenia, the aim is to maxi-
mise muscle in youth and young adulthood, maintain muscle
in middle age and minimise loss in older age (Figure 3) [25].
Categories of sarcopenia and sarcopenia-
like conditions
Primary and secondary sarcopenia
In some individuals, sarcopenia is largely attributable to ageing;
in many cases, other causes can be identified. Thus, the categor-
ies of primary sarcopenia and secondary sarcopenia may be
useful in clinical practice (Figure 4) [1]. Sarcopenia is considered
‘primary’ (or age-related) when no other specific cause is evi-
dent, while sarcopenia is considered ‘secondary’ when causal
factors other than (or in addition to) ageing are evident.
Sarcopenia can occur secondary to a systemic disease, especially
one that may invoke inflammatory processes, e.g. malignancy or
organ failure. Physical inactivity also contributes to development
of sarcopenia, whether due to a sedentary lifestyle or to disease-
related immobility or disability [132]. Further, sarcopenia can
develop as a result of inadequate intake of energy or protein,
which may be due to anorexia, malabsorption, limited access to
healthy foods or limited ability to eat.
Acute and chronic sarcopenia
EWGSOP2 newly identifies subcategories of sarcopenia as
acute and chronic. Sarcopenia that has lasted less than 6
months is considered an acute condition, while sarcopenia last-
ing ≥6 months is considered a chronic condition. Acute sarco-
penia is usually related to an acute illness or injury, while
chronic sarcopenia is likely to be associated with chronic and
progressive conditions and increases the risk of mortality. This
distinction is intended to underscore the need to conduct peri-
odic sarcopenia assessments in individuals who may be at risk
for sarcopenia in order to determine how quickly the condition
is developing or worsening. Such observations are expected to
facilitate early intervention with treatments that can help prevent
or delay sarcopenia progression and poor outcomes.
Sarcopenic obesity
Sarcopenic obesity is a condition of reduced lean body mass
in the context of excess adiposity [133]. Sarcopenic obesity is
most often reported in older people, as both risk and preva-
lence increase with age [134]. Obesity exacerbates sarcopenia,
increases the infiltration of fat into muscle, lowers physical
function and increases risk of mortality [135–138].
A. J. Cruz-Jentoft et al.
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Sarcopenic obesity is a distinct condition, and there are
ongoing initiatives to improve its definition. Sarcopenic obes-
ity is therefore outside of the scope of this article.
Frailty
Frailty is a multidimensional geriatric syndrome that is char-
acterised by cumulative decline in multiple body systems or
functions [139, 140], with pathogenesis involving physical as
well as social dimensions [141]. Frailty increases vulnerability
to poor health outcomes such as disability, hospital admis-
sion, reduced quality of life and even death [141, 142].
The physical phenotype of frailty, described by Fried and
co-workers [143], shows significant overlap with sarcopenia;
low grip strength and slow gait speed are characteristic of
both. Weight loss, another diagnostic criterion for frailty, is
also a major etiologic factor for sarcopenia. Treatment
options for physical frailty and for sarcopenia likewise over-
lap—provision of optimal protein intake, supplementation of
vitamin D, and physical exercise [19, 144, 145].
Taken together, frailty and sarcopenia are still distinct—
one a geriatric syndrome and the other a disease. While sar-
copenia is a contributor to the development of physical
frailty, the syndrome of frailty represents a much broader
concept. Frailty is seen as the decline over a lifetime in mul-
tiple physiological systems, resulting in negative conse-
quences to physical, cognitive, and social dimensions.
Frailty’s diagnostic tools reflect these multiple dimensions,
e.g. the Groningen Frailty Indicator, the Frailty Index of
Rockwood et al. and others [146–149].
Malnutrition-associated sarcopenia
The sarcopenia phenotype is also associated with malnutri-
tion, regardless of whether the malnourished condition is
rooted in low dietary intake (starvation, inability to eat),
reduced nutrient bioavailability (e.g. with diarrhea, vomiting)
or high nutrient requirements (e.g. with inflammatory dis-
eases such as cancer or organ failure with cachexia) [150,
151]. Low muscle mass has recently been proposed as part
of the definition of malnutrition [152]. Also in malnutrition,
low fat mass is usually present, which is not necessarily the
case in sarcopenia [151, 152].
Looking ahead: gaps in sarcopenia research
There are still many gaps in our knowledge about sarcope-
nia—its initiation and progression, diagnostic tools and cut-
off points, and outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. EWGSOP2 sarcopenia cut-off points
Test Cut-off points for men Cut-off points for women References
EWGSOP2 sarcopenia cut-off points for low strength by chair stand and grip strength
Grip strength <27 kg <16 kg Dodds (2014) [26]
Chair stand >15 s for five rises Cesari (2009) [67]
EWGSOP2 sarcopenia cut-off points for low muscle quantity
ASM <20 kg <15 kg Studenski (2014) [3]
ASM/height2 <7.0 kg/m2 <6.0 kg/m2 Gould (2014) [125]
EWGSOP2 sarcopenia cut-off points for low performance
Gait speed ≤0.8 m/s Cruz-Jentoft (2010) [1]
Studenski (2011) [84]
SPPB ≤8 point score Pavasini (2016) [90]
Guralnik (1995) [126]
TUG ≥20 s Bischoff (2003) [127]
400 m walk test Non-completion or ≥6 min for completion Newman (2006) [128]
LOW
LOW
POSITIVE
OR PRESENT
Muscle
assessment
Mass, Quality
PHYSICAL 
PERFORMANCE
SPPB, TUG, 400m
Sarcopenia 
confirmed
LOW
CONFIRM 
FIND CASES
ASSESS
Musclestrength
Grip strength, 
chairstands
NORMAL
SARC-F
or clinical
suspicion
No sarcopenia;
rescreen later 
Sarcopenia
probable*
NEGATIVE
Muscle quantity
or quality
DXA; BIA, CT, MRI
hysical
Performance
Gait speed, SPPB,
TUG, 400m walk 
Sarcopenia
confirmed
Sarcopenia
severeSEVERITY
Muscle t
Gri  t t ,
Chair stand test
No sarcopenia;
rescreen later
In clinical practice,
this is enough to
trigger assessment of
causes and start
intervention
NORMAL
Figure 1. Sarcopenia: EWGSOP2 algorithm for case-finding,
making a diagnosis and quantifying severity in practice. The
steps of the pathway are represented as Find-Assess-Confirm-
Severity or F-A-C-S. *Consider other reasons for low muscle
strength (e.g. depression, sroke, balance disorders, peripheral
vascular disorders).
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Some suggested areas for further study are listed below.
• What are the influences operating to cause and worsen
sarcopenia, and what are the opportunities for interven-
tion across the life course?
• How can we identify older persons at high risk of sarco-
penia, and what preventive actions are preferred?
• For sarcopenia diagnosis, some cut-off points are arbitrary
at this time; the development of validated cut-off points
will depend on normative data and their predictive value
for hard end-points—a high priority for research studies.
• For stature-dependent measures of sarcopenia and its risk
(gait speed, muscle strength), studies are needed to estab-
lish if gender-specific and region-specific threshold values
for sarcopenia diagnosis improve prediction of outcomes.
• What muscle quality indicators best predict outcomes?
How can we best assess muscle quality? What tools and
measurements are accurate and affordable?
• What are the kinetics of muscle loss in different people
and circumstances, as detected by multiple measurements?
What are differences in causes and consequences of grad-
ual versus rapid loss?
• What outcomes are best used as sensitive measures of
response to sarcopenia treatments?
Summary and call-to-action
Sarcopenia, i.e. muscle failure, is a muscle disease rooted in
adverse muscle changes that accrue across a lifetime; sarco-
penia is common among adults of older age but can also
occur earlier in life. Sarcopenia is defined by low levels of
measures for three parameters: (1) muscle strength, (2)
muscle quantity/quality and (3) physical performance as an
indicator of severity.
Although research findings over the last decade have
answered many questions, other findings raised more areas
for researchers to address in the future. Thus, a clear defin-
ition of sarcopenia, as well as clear diagnostic criteria, are
necessary to guide both clinical practice and research design
for the future.
Figure 2. Normative data for grip strength across the life course in men and women in the UK (Dodds RM, et al. PLoS One.
2014;9:e113637). Centiles shown are 10th, 25th, 50th, 75th and 90th. Cut-off points based on T-score of ≤ -2.5 are shown for
males and females (≤27 kg and 16 kg, respectively). Color-coding represents different birth cohorts used for the study
(Figure adapted with permission from R Dodds and PLOS One).
Early life
Maximize peak
Age
M
u
sc
le
 s
tr
en
g
th
Adult life
Maintain peak
Older life
Minimize loss
Threshold of disability
Threshold of low physical performance
Range of 
strength in 
individuals
Figure 3. Muscle strength and the life course. To prevent or
delay sarcopenia development, maximise muscle in youth and
young adulthood, maintain muscle in middle age and minimise
loss in older age
Aging
Disease
Inactivity
Malnutrition
• Age-associated muscle loss
• Inflammatory conditions (e.g., organ failure,
   malignancy) 
• Osteoarthritis
• Neurological disorders
• Sedentary behavior (e.g., limited mobility
   or bedrest) 
• Physical inactivity
• Under-nutrition or malabsorption
• Medication-related anorexia
• Over-nutrition/obesity
Figure 4. Factors that cause and worsen muscle quantity and
quality, sarcopenia, are categorised as primary (ageing) and second-
ary (disease, inactivity, and poor nutrition). Because a wide range
of factors contribute to sarcopenia development, numerous muscle
changes seem possible when these multiple factors interact.
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For screening and diagnosis of sarcopenia,
EWGSOP recommends following the pathway: Find
cases-Assess-Confirm-Severity (F-A-C-S).
Find-cases: To identify individuals at risk for sarcope-
nia, EWGSOP advises use of the SARC-F questionnaire or
clinical suspicion to find sarcopenia-associated symptoms.
Assess: To assess for evidence of sarcopenia,
EWGSOP recommends use of grip strength or a chair
stand measure with specific cut-off-points for each test.
For special cases and for research studies, other methods
for measurement of strength (knee flexion/extension) can
be used.
Confirm: To confirm sarcopenia by detection of low
muscle quantity and quality, DXA is advised in clinical
practice, and DXA, BIA, CT or MRI in research studies.
Determine Severity: Severity can be evaluated by per-
formance measures; gait speed, SPPB, TUG and 400-m
walk tests can be used.
EWGSOP2’s updated recommendations aim to increase
awareness of sarcopenia and its risk. With these new
recommendations, EWGSOP2 calls for healthcare profes-
sionals who treat patients at risk for sarcopenia to take
actions that will promote early detection and treatment. We
also encourage more research in the field of sarcopenia in
order to prevent or delay adverse outcomes that also incur
a heavy burden for patients and healthcare systems.
Key points
• In the updated definition of sarcopenia, EWGSOP2 ele-
vates low strength to the forefront as a primary indicator
of probable sarcopenia.
• Sarcopenia is now defined as a muscle disease that may
be acute or chronic.
• We recommend an algorithm for case-finding, diagnosis,
and severity determination for systematic and consistent
identification of people with sarcopenia or its risk.
• We recommend simple, specific cut-off points for mea-
sures that identify and characterize sarcopenia.
• These new recommendations are aimed at facilitating early
detection and better treatment of sarcopenia in clinical
practice.
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